Cancer Stem Cell News Volume 10.36 | Sep 15 2021


    2021-09-15 | CSCN 10.36

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.36 – 15 September, 2021

    STRAP is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis through a Feed-Forward Mechanism

    Researchers generated Strap intestinal epithelial knockout mice by crossing mice containing floxed alleles of Strap with Villin-Cre mice. They used human colon cancer cell lines and human and mouse colon tumor-derived organoids for STRAP knockdown/knockout and overexpression experiments.

    Subscribe to the Stem Cell Podcast newsletter for a chance to win a bluetooth speaker.
    PUBLICATIONSRanked by the impact factor of the journal

    Δ133p53β Isoform Pro-Invasive Activity Is Regulated through an Aggregation-Dependent Mechanism in Cancer Cells

    The authors reported that Δ133p53β activity was regulated through an aggregation-dependent mechanism. Δ133p53β aggregates were observed in cancer cells and tumor biopsies.
    [Nature Communications]

    Full Article

    Viral Targeting of Glioblastoma Stem Cells with Patient-Specific Genetic and Post-Translational p53 Deregulations

    Investigators dissected the genetic and functional heterogeneity of human glioblastoma stem cells within patients by their innate responses to non-pathogenic mouse parvoviruses that were tightly restrained by cellular physiology.
    [Cell Reports]

    Full Article

    EMP3 Negatively Modulates Breast Cancer Cell DNA Replication, DNA Damage Repair, and Stem-Like Properties

    In silico analysis showed that epithelial membrane protein 3 (EMP3) was associated with favorable survival, and negatively regulated cell cycle S-phase. Loss and gain of function studies demonstrated that EMP3 inhibited breast cancer cell S-phage entry, DNA replication, DNA damage repair, and stem-like properties.
    [Cell Death & Disease]

    Full Article

    Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model

    Researchers characterized the time-dependent impact of regadenoson on brain endothelial cell interactions and paracellular transport, using mouse and rat brain endothelial cells and tumor models.
    [Molecular Cancer Research]


    A Direct Negative Feedback Loop of miR-4721/FOXA1/Nanog Promotes Nasopharyngeal Cell Stem Cell Enrichment and Metastasis

    In vivo and in vitro metastasis assays confirmed miR-4721 promoted cell migration and invasion. Tumor spheroid formation assay, side population assay, and ALDEFLUOR assay verified miR-4721 regulated cancer stem cell-like properties.
    [Journal of Translational Medicine]

    Full Article

    Down-Regulation of lncRNA MEG3 Promotes Chronic Low Dose Cadmium Exposure-Induced Cell Transformation and Cancer Stem Cell-Like Property

    The long non-coding RNA microarray analysis showed that the expression level of a tumor suppressive lncRNA maternally expressed 3 was significantly down-regulated in cadium-transformed cells, which was confirmed by further q-PCR analysis.
    [Toxicology and Applied Pharmacology]


    Exosomal MicroRNA-19b Targets FBXW7 to Promote Colorectal Cancer Stem Cell Stemness and Induce Resistance to Radiotherapy

    The regulatory role of miR-19b in colorectal CSCs and radiotherapy-resistant cells was determined using miRNA microarray analysis, and its prognostic value was probed using the TCGA database.
    [Kaohsiung Journal of Medical Sciences]

    Full Article

    HN1L Promotes Stem Cell-Like Properties by Regulating TGF-β Signaling Pathway through Targeting FOXP2 in Prostate Cancer

    CD133+ cells were sorted from prostate cancer cells using magnetic fluorescence cell sorting technology and were considered as CSCs.
    [Cell Biology International]


    Cancerous and Non-Neoplastic Stem Cells in the Stomach Similarly Express CD44 and CD133

    Scientists investigated the expression of CD44 and CD133 in gastric cancer and non-neoplastic gastric mucosa. They used samples of primary gastric adenocarcinomas, metastatic lymph nodes, intestinal metaplasia, and histologically normal gastric tissues of surgical margins.
    [Acta Histochemica]


    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.

    Cancer Stem Cells in Hepatocellular Carcinoma – from Origin to Clinical Implications

    The authors comprehensively describe developments in the liver CSC field with emphasis on experiments utilizing single-cell transcriptomics to understand liver CSC heterogeneity, lineage-tracing and cell-ablation studies of liver CSCs, and the influence of the CSC niche and tumour microenvironment on liver cancer stemness, including interactions between CSCs and the immune system.
    [Nature Reviews Gastroenterology & Hepatology]


    The Emerging Role of miR-200 Family in Metastasis: Focus on EMT, CSCs, Angiogenesis, and Anoikis

    Investigators present the molecular pathways by which the miR 200 family manifests its effects on EMT, cancer stem cells, angiogenesis, anoikis, and the effects of tumor cell metastases.
    [Molecular Biology Reports]

    AbstractGraphical Abstract

    Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-Line Treatment of Metastatic Pancreatic Cancer

    Novocure announced that it has entered into a clinical trial collaboration agreement with Roche, to develop Tumor Treating Fields together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma.
    [Novocure, GmbH]

    Press Release

    PureTech Founded Entity Vor Biopharma Announces VOR33 Granted US FDA Fast Track Designation for Acute Myeloid Leukemia

    PureTech Health plc announced that its Founded Entity, Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, Vor’s lead engineered hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukemia.
    [PureTech Health plc]

    Press Release

    Researchers Awarded $31 Million for Clinical Trials to Treat Stroke, Heart Failure, Brain Cancer

    The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million.
    [Stanford Medicine]

    Press Release

    Cambridge Cancer Epigenetics Club: Matthias Merkenschlager

    Nov 5, 2021

    > See All Events


    Postdoctoral Fellow – Pancreatic Cancer Heterogeneity

    LIRCCS Candiolo Cancer Institute – Turin, Italy

    Postdoctoral Position – Cancer Biology

    Houston Methodist Research Institute – Houston, Texas, United States

    Senior Scientific Officer – Cancer Cells in Metastatic Microenvironments

    CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom

    PhD Student – Tumor Immunology

    University Hospital of Bern – Bern, Switzerland

    Senior Researcher – Genomic and Epigenetic Changes of Rare Tumors

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter